Drugs / VISLARAFUSP ALFA
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT05076591 | Jun 2022 → Dec 2024 | breast cancer, gastric cancer | ImmuneOnco Biopharmaceuticals (Shanghai) Inc. | Suspended | No outcome recorded Stop: Business |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT05805956 | Feb 2022 → Oct 2024 | cholangiocarcinoma, gastric carcinoma, lung cancer | ImmuneOnco Biopharmaceuticals (Shanghai) Inc. | Unknown | No outcome recorded |
News releases announcing trial results or a regulatory action · 2
| Date | Issuer | Release |
|---|---|---|
| 2021-08-21 | ImmuneOnco Biopharmaceuticals (Shanghai) Inc. | Regulatory 宜明昂科IMM2902项目获得美国FDA临床试验研究许可 immuneonco.com ↗
2021年8月21日，宜明昂科宣布，全球首个靶向人CD47 x HER2的双靶点抗体-受体重组蛋白药物 (项目编号:IMM2902）在美国的新药临床研究申请 (IND) 已获得美国食品药品监督管理局 (FDA) 许可，相关适应症为HER2阳性的晚期实体瘤。 |
| 2021-06-30 | ImmuneOnco Biopharmaceuticals (Shanghai) Inc. | Regulatory 宜明昂科CD47xHer2 双抗项目获得国家药监局批准临床试验 immuneonco.com ↗
2021年6月30日，宜明昂科宣布，全球首个靶向人CD47xHer2的双靶点抗体-受体重组蛋白药物(项目编号:IMM2902）获得国家药监局(NMPA)临床试验批准。 |
All press releases naming this drug 2 releases
| Date | Issuer | Release |
|---|---|---|
| 2021-08-21 | ImmuneOnco Biopharmaceuticals (Shanghai) Inc. | 宜明昂科IMM2902项目获得美国FDA临床试验研究许可 immuneonco.com ↗ |
| 2021-06-30 | ImmuneOnco Biopharmaceuticals (Shanghai) Inc. | 宜明昂科CD47xHer2 双抗项目获得国家药监局批准临床试验 immuneonco.com ↗ |
Evidence & citations 6 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | VISLARAFUSP ALFA | ChEMBL registry synonym — accepted as the source's own label CHEMBL6068189 ↗ |
| Known as | IMM2902 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05805956 ↗ |
| Modality | Monoclonal antibody | “a recombinant bispecific monoclonal antibody with high affinity to the dual targets, HER2 and CD47” NCT05076591 ↗ |
| Route | Intravenous | “through intravenous administration weekly up to 48 weeks” NCT05076591 ↗ |
| Target | CD47 | “the dual targets, HER2 and CD47” NCT05076591 ↗ |
| Target | HER2 | “the dual targets, HER2 and CD47” NCT05076591 ↗ |